Article
Acquisition of resistance to ceftazidime-avibactam during infection treatment in Pseudomonas aeruginosa through D179Y mutation in one of two blaKPC-2 gene copies without losing carbapenem resistance.
Frontiers in cellular and infection microbiology - 1 Jan 2022
García Patricia, Brito Bárbara, Alcalde-Rico Manuel, Munita José M, Martínez Jose R W, Olivares-Pacheco Jorge, Quiroz Valeria, Wozniak Aniela
Abstract excerpt
Ceftazidime/Avibactam (CAZ/AVI) is frequently used to treat KPC-producing Pseudomonas aeruginosa (KPC-PA) and Enterobacterales. CAZ/AVI resistance is driven by several mechanisms. In P. aeruginosa this mainly occurs through alteration of AmpC, porins, and/or efflux pump overexpression, whereas in Enterobacterales it frequently occurs through D179Y substitution in the active site of KPC enzyme. This aminoacid...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.